Stockreport

Shattuck plunges after discontinuing lead candidate [Seeking Alpha]

ONO PHARM CO UNSP/ADR  (OPHLY) 
NASDAQ:AMEX Investor Relations: ono.co.jp/eng/investor/index.html
PDF The decision came after an interim Phase 1 readout indicated that SL-172154, compared to azacitidine monotherapy, failed to improve median overall survival in certain p [Read more]